Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection (Q41429010)

30 September 2017

1 reference

title

Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection (English)

1 reference

30 September 2017

1 reference

Perry CM

1

1 reference

PubMed ID

9098665

30 September 2017

Faulds D

series ordinal

2

1 reference

30 September 2017

1 April 1997

1 reference

30 September 2017

1 reference

30 September 2017

53

1 reference

30 September 2017

657-680

1 reference

30 September 2017

4

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199753040-00008

30 September 2017

0 references

cites work

Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro

1 reference

12 December 2020

Comparison of cytotoxicity of the (-)- and (+)-enantiomer of 2',3'-dideoxy-3'-thiacytidine in normal human bone marrow progenitor cells

1 reference

12 December 2020

Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides

1 reference

12 December 2020

Exacerbation of peripheral neuropathy by lamivudine

1 reference

12 December 2020

HIV-1 RNA levels and the development of clinical disease. North American Lamivudine HIV Working Group

1 reference

12 December 2020

Clinical pharmacokinetics of nucleoside antiretroviral agents

1 reference

12 December 2020

The intracellular phosphorylation of (-)-2'-deoxy-3'-thiacytidine (3TC) and the incorporation of 3TC 5'-monophosphate into DNA by HIV-1 reverse transcriptase and human DNA polymerase gamma

1 reference

12 December 2020

Viral resistance and the selection of antiretroviral combinations

1 reference

12 December 2020

Consensus symposium on combined antiviral therapy. International Society for Antiviral Research and the National Institutes of Allergy and Infectious Diseases

1 reference

12 December 2020

Activities of the four optical isomers of 2',3'-dideoxy-3'-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes

1 reference

12 December 2020

The XI international conference on AIDS. Vancouver 7-12 July 1996. A review of Clinical Science Track B.

1 reference

12 December 2020

The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection

1 reference

12 December 2020

Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex

1 reference

12 December 2020

Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC

1 reference

12 December 2020

Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party

1 reference

12 December 2020

HIV pathogenesis and treatment strategies

1 reference

12 December 2020

Favorable interaction of beta-L(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus

1 reference

12 December 2020

Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine

1 reference

12 December 2020

Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group

1 reference

12 December 2020

In vitro comparison of selected triple-drug combinations for suppression of HIV-1 replication: the Inter-Company Collaboration Protocol

1 reference

12 December 2020

Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole

1 reference

12 December 2020

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy

1 reference

12 December 2020

Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro

1 reference

12 December 2020

Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party

1 reference

12 December 2020

High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase

1 reference

12 December 2020

Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (--)-2',3'-dideoxy-3'-thiacytidine

1 reference

12 December 2020

(-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro

1 reference

12 December 2020

Triple combinations: present and future.

1 reference

12 December 2020

Nucleoside reverse transcriptase inhibitors and resistance of human immunodeficiency virus type 1.

1 reference

12 December 2020

Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients.

1 reference

12 December 2020

Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells.

1 reference

12 December 2020

Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase

1 reference

12 December 2020

Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog

1 reference

12 December 2020

Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction.

1 reference

12 December 2020

Pharmacokinetics of lamivudine and BCH-189 in plasma and cerebrospinal fluid of nonhuman primates

1 reference

12 December 2020

From the Centers for Disease Control and Prevention. Update: provisional public health service recommendations for chemoprophylaxis after occupational exposure to HIV

1 reference

12 December 2020

Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).

1 reference

12 December 2020

The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro

1 reference

12 December 2020

Selection in vitro of an HIV-1 variant resistant to both lamivudine (3TC) and zidovudine

1 reference

12 December 2020

Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA.

1 reference

12 December 2020

Combination Antiretroviral Therapy

1 reference

12 December 2020

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

1 reference

12 December 2020

Clinical toxicity of antiretroviral nucleoside analogs

1 reference

12 December 2020

Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences

1 reference

12 December 2020

The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine

1 reference

12 December 2020

Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.

1 reference

12 December 2020

A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection

1 reference

12 December 2020

Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex.

1 reference

12 December 2020

Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study

1 reference

12 December 2020

Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group

1 reference

12 December 2020

Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation

1 reference

12 December 2020

Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine

1 reference

12 December 2020

Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood--France, United Kingdom, and United States, January 1988-August 1994

1 reference

12 December 2020

Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy

1 reference

12 December 2020

Determination of 2'-deoxy-3'-thiacytidine (3TC) in human urine by liquid chromatography: direct injection with column switching

1 reference

12 December 2020

Cellular metabolism of (−) enantiomeric 2′-deoxy-3′-thiacytidine

1 reference

12 December 2020

Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma

1 reference

12 December 2020

Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase

1 reference

12 December 2020

Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2'-deoxycytidine kinase

1 reference

12 December 2020

High-performance liquid chromatographic assay for 2'-deoxy-3'-thiacytidine in human serum

1 reference

12 December 2020

Biochemical pharmacology of (+)- and (-)-2',3'-dideoxy-3'-thiacytidine as anti-hepatitis B virus agents

1 reference

12 December 2020

10.2165/00003495-199753040-00008

Identifiers

DOI

1 reference

PubMed ID

9098665

Dimensions Publication ID

30 September 2017

0 references

1 reference

PubMed ID

9098665